Table 2.

The fibrosis indexes of the study subjects in the PSM cohorts

Variables	Tamoxifen (n = 154)	Toremifene (n = 154)	P-value
APRI at baseline	0.23 [0.19–0.30]	0.22 [0.18–0.27]	0.052
APRI at follow-up time	0.30 [0.26–0.37]	0.25 [0.22–0.34]	< 0.001
P-value	< 0.001	< 0.001
Medium or high APRI at baseline	4 (2.6)	3 (1.9)	1.000
Medium or high APRI at follow-up time	15 (9.7)	4 (2.6)	0.009
P-value	0.009	1.000
FIB-4 at baseline	0.99 [0.79–1.20]	0.93 [0.77–1.11]	0.095
FIB-4 at follow-up time	1.13 [0.92,1.35]	1.04 [0.87,1.30]	0.034
P-value	< 0.001	< 0.001
Medium or high FIB-4 at baseline	28 (18.2)	18 (11.7)	0.110
Medium or high FIB-4 at follow-up time	45 (29.2)	37 (24.0)	0.302
P-value	0.023	0.004

Statistically significant values are highlighted in italics

Data are presented as the mean ± standard deviation, median [interquartile range] or number (%)

Abbreviations: APRI aspartate aminotransferase-platelet ratio index; FIB-4 Fibrosis- 4 index